PRINIVIL Drug Patent Profile

When do Prinivil patents expire, and what generic alternatives are available?

Prinivil is a drug marketed by Merck and is included in one NDA.

The generic ingredient in PRINIVIL is lisinopril. There are twenty-one drug master file entries for this compound. Thirty-six suppliers are listed for this compound. Additional details are available on the lisinopril profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Prinivil

A generic version of PRINIVIL was approved as lisinopril by ANNORA PHARMA on July 1^st, 2002.

Summary for PRINIVIL

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for PRINIVIL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Merck	PRINIVIL	lisinopril	TABLET;ORAL	019558-006	Jan 28, 1994		DISCN	No	No
Merck	PRINIVIL	lisinopril	TABLET;ORAL	019558-003	Dec 29, 1987		DISCN	No	No
Merck	PRINIVIL	lisinopril	TABLET;ORAL	019558-001	Dec 29, 1987		DISCN	No	No
Merck	PRINIVIL	lisinopril	TABLET;ORAL	019558-002	Dec 29, 1987		DISCN	No	No
Merck	PRINIVIL	lisinopril	TABLET;ORAL	019558-004	Oct 25, 1988		DISCN	No	No

International Patents for PRINIVIL

See the table below for patents covering PRINIVIL around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	S5581845	AMINO ACID DERIVATIVE AS ANTIHYPERTENSIVE
Canada	1276559	COMPOSITION A BASE DE DERIVES D'ACIDES AMINES EN ASSOCATION AVEC DES DIURETIQUES (AMINOACID DERIVATIVES COMPOSITION IN ASSOCIATION WITH DIURETIC AGENTS)
Japan	H0442400
Czechoslovakia	237326	METHOD OF PREPARATION OF CARBOXYALKYLDIPEPTIDE
Bulgaria	39467	METHOD FOR PREPARING OF CARBOXYALKYL DIPEPTIDES
Poland	131140

Investment Scenario and Fundamentals Analysis for PRINIVIL

Last updated: February 20, 2026

What Is PRINIVIL?

PRINIVIL is the brand name for the drug enalapril maleate, an ACE (angiotensin-converting enzyme) inhibitor used primarily for treating hypertension, congestive heart failure, and diabetic nephropathy. Its patent expired in many markets, leading to a shift toward generic versions.

Market Overview

Parameter	Data	Source
Market size (2022)	~$2.8 billion globally	IQVIA (2022)
Growth rate (CAGR 2023-27)	3-4%	Market Research Future (2023)
Leading markets	US, Europe, Japan	IMS Health
Key competitors	Generic ENalapril brands, Teva, Mylan	Market reports

Patent and Regulatory Status

• Patent expiry occurred in the US in 2010, opening the market to generic competition.
• In the European Union, patent expiry was in 2010 as well.
• Current approvals include generic versions globally.

Supply Chain & Manufacturing

• Several manufacturers produce enalapril, relying on active pharmaceutical ingredient (API) suppliers primarily in India and China.
• Market entry barriers are low due to generic status, but manufacturing costs and quality control remain critical factors.

Key Drivers

1. Growing hypertension prevalence: Over 1.2 billion globally, driving steady demand.
2. Increasing geriatric population: A larger elderly cohort with higher hypertension incidence.
3. Cost-effectiveness of generics: A shift toward affordable treatments fuels volume growth.

Investment Considerations

Competitive Landscape

• The market for enalapril is saturated with multiple generic manufacturers.
• Price competition has compressed margins.
• Brand PRINIVIL is less prominent given market penetration by generics.

Patent and Legal Risks

• No patent restrictions exist; legal barriers are minimal.
• Generic manufacturers face patent challenges and litigation, but these are declining with patent expiry.

Regulatory Risks

• Stringent quality standards under agencies like the FDA and EMA.
• Potential regulatory delays if manufacturing adherence is compromised.

Market Trends

• Shift toward combination therapies for hypertension.
• Growing preference for fixed-dose combinations (FDCs), possibly reducing demand for monotherapy like PRINIVIL.

Financial Outlook

• Revenue for PRINIVIL has declined post-patent expiry.
• Future growth depends on brand loyalty, marketing, and potential new formulations.

Investment Risks

• Intense competition exerts downward pressure on price.
• Market saturation limits growth potential for existing formulations.
• Regulatory shifts or quality concerns can impact supply and sales.

Strategic Opportunities

• Portfolio expansion into combination products.
• Innovation in delivery mechanisms (e.g., fixed-dose combos or sustained-release forms).
• Geographic expansion into emerging markets with rising hypertension prevalence.

Summary

The investment outlook for PRINIVIL hinges on its position as a mature drug with declining sales in developed markets due to generic competition. Growth opportunities are limited but present in emerging markets, formulation innovation, and combination therapies. Risks include pricing pressures and market saturation.

Key Takeaways

• PRINIVIL's original patent has expired, resulting in significant generic competition.
• The global enalapril market is growing modestly, primarily driven by hypertension prevalence.
• Market competition has lowered margins but created opportunities in emerging markets.
• Future growth depends on adding value via formulations or geographic expansion.
• Risks include price pressures, reduced demand from combination therapies, and regulatory challenges.

FAQs

Q1: What is the current patent status of PRINIVIL?
A1: The patent expired in the US and EU around 2010, allowing generic competition.

Q2: Who are the main competitors in the enalapril market?
A2: Generic manufacturers such as Teva, Mylan, and local producers dominate.

Q3: How has the market for PRINIVIL changed post-patent expiry?
A3: Sales declined due to generic price competition, but volume sales remain stable in certain regions.

Q4: Are there new formulations of enalapril in development?
A4: Limited newer formulations exist; most focus on market expansion and combination therapies.

Q5: What are the primary growth regions?
A5: Emerging markets like China, India, and parts of Latin America exhibit increasing hypertension prevalence and higher treatment uptake.

---

References

[1] IQVIA. (2022). Global Prescription Market Data.
[2] Market Research Future. (2023). Hypertension Drugs Market Report.
[3] U.S. Food and Drug Administration. (2010). Patent expiry notices for enalapril.